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Background: Previous studies have shown that Mycobacterium tuberculosis (MTB) Uganda family, a sub-lineage of
the MTB Lineage 4, is the main cause of tuberculosis (TB) in Uganda. Using a well characterized patient population,
this study sought to determine whether there are clinical and patient characteristics associated with the success of
the MTB Uganda family in Kampala.
Methods: A total of 1,746 MTB clinical isolates collected from1992-2009 in a household contact study were
genotyped. Genotyping was performed using Single Nucleotide Polymorphic (SNP) markers specific for the MTB
Uganda family, other Lineage 4 strains, and Lineage 3, respectively. Out of 1,746 isolates, 1,213 were from patients
with detailed clinical data. These data were used to seek associations between MTB lineage/sub-lineage and patient
phenotypes.
Results: Three MTB lineages were found to dominate the MTB population in Kampala during the last two decades.
Overall, MTB Uganda accounted for 63% (1,092/1,746) of all cases, followed by other Lineage 4 strains accounting
for 22% (394/1,746), and Lineage 3 for 11% (187/1,746) of cases, respectively. Seventy-three (4 %) strains remained
unclassified. Our longitudinal data showed that MTB Uganda family occurred at the highest frequency during the
whole study period, followed by other Lineage 4 strains and Lineage 3. To explore whether the long-term success
of MTB Uganda family was due to increased virulence, we used cavitary disease as a proxy, as this form of TB is the
most transmissible. Multivariate analysis revealed that even though cavitary disease was associated with known risk
factors such as smoking (adjusted odds ratio (aOR) 4.8, 95% confidence interval (CI) 3.33-6.84) and low income
(aOR 2.1, 95% CI 1.47-3.01), no association was found between MTB lineage and cavitary TB.
Conclusion: The MTB Uganda family has been dominating in Kampala for the last 18 years, but this long-term
success is not due to increased virulence as defined by cavitary disease.
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Globally there are seven human-associated Mycobacterium
tuberculosis complex (MTBC) lineages that are differen-
tially distributed with certain lineages predominating in
certain geographical regions and human populations
[1-4]. Increasing evidence shows that these lineages dif-
fer in pathogenesis in animal models, but their differen-
tial impact on tuberculosis (TB) in humans is not clear
[3]. There is also inconclusive data with respect to
whether the distribution of MTBC lineages/sublineages
is due to host and or microbial factors [3,5,6]. Recent
studies in Uganda indicated that the majority of TB
cases are due to the MTBC Uganda family (L4-U) [7,8],
a sub-lineage of Lineage 4 defined by a deletion in the
Region of Difference (RD) 724, the spoligotype finger
print (33–36, 40 and 43 spacers missing), and several
SNPs [1,9,10]. Although earlier studies had defined this
L4-U family as Mycobacterium africanum sub-type II
based on colony morphology and biochemical tests
[11,12], advances in molecular classification have led to
its reclassification as M. tuberculosis sensu stricto [13].
The resurgence of TB calls for improved understanding
of the epidemiology, pathogenesis, chemotherapy, and gen-
etic variability of the causative agent for better control of
the disease. Studies so far offer limited information about
the kinetics of L4-U, and do not explain why this family of
MTBC is so predominant in Uganda. However, it is now
apparent that host, environment and microbiological fac-
tors are likely to play a role [2,9,14-22]. For instance, the
dominance of Lineage 2 (which includes the Beijing family
of MTBC) in Asia and its wide geographical distribution
might be partially due to higher virulence (as determined
in animal models) and its association with drug resistance
[23-25]. Furthermore, based on the long-standing associ-
ation between MTBC and its human host, some studies
have proposed that the different MTBC lineages might
have adapted to different human populations, perhaps as a
consequence of co-evolutionary processes [1,6,23,26-28].
With the advent of robust molecular markers and a well
characterized large human population cohort, genetic vari-
ability in MTBC clinical isolates and clinical phenotypes
can be better described, and thus the reason of dominance
of certain MTBC lineages may be deduced [3]. In this
study we used MTBC isolates collected from patients par-
ticipating in two large prospective community-based TB
transmission studies carried out in peri-urban Kampala
from 1992–2009 to establish trends in the prevalence of
the various MTBC lineages over time, and examine the as-
sociation of MTBC lineages with patient characteristics.
Methods
Patient recruitment and collection of MTBC isolates
The isolates used in this study were collected from pa-
tients recruited in two studies that were both carried outin peri-urban Kampala-Uganda in sequence. An initial
household contact study (HC) was conducted from
1992 to 1999 to describe the epidemiology of TB
[population 1.7 million; population density 9400/km2
(Uganda Bureau of Statistics; www.ubos.org, 2011) and
[29,30]. The second study is the Kawempe Community
Health study (KCH) that started in 2000 and is on-
going. The KCH focuses on host factors associated with
primary infection, re-infection, reactivation, and pro-
gression from MTB infection to active TB clinical dis-
ease and also identifies and tracks strains of MTB
circulation in households and the local community.
During the conduct of these epidemiologic cohort
studies (HC and KCH), adults with sputum smear posi-
tive TB were consecutively enrolled as index cases. An
index case was defined as the first TB case identified in
a household who was ≥ 18 years of age and lived with
one or more household contacts. A household was de-
fined as a group of people living within one residence,
share meals together and identified a head of family who
made decisions for the household. Following the identifi-
cation of the index cases, home health visitors contacted
the household contacts for health education about TB
and the study. A household contact was defined as any
individual who had resided in the household for at least
7 consecutive days during the 3 months prior to the
diagnosis of TB in the index case. Household contacts
were screened for both latent (tuberculin skin test) and
active disease (sputum smear and culture) on first con-
tact. Those found not to have TB according to the study
protocol were followed every three months for a period
of two years to identify contacts that later developed
active TB. Household contacts were classified as co-
prevalent cases if active TB was present at baseline or
during three months of household follow-up and as inci-
dent cases if active TB developed after three months of
follow-up. In both studies (HC and KCH) a total of 1746
isolates were stored from the study area over the period
of study (1995–2009). Patients with either latent or ac-
tive TB were treated with isoniazid (INH) preventive
therapy or standard short course combination chemo-
therapy for active TB in accordance with the Uganda
National TB and Leprosy Program guidelines.
At baseline, data of enrolled patients, including age,
sex, HIV status, presence of cavity, ethnicity, status of
smoking, Body Mass Index (BMI), level of education, al-
cohol drinking, income, history of diabetes, presence of
BCG scar, night sweats, TB in the past, hemoptysis,
swollen lymph nodes, extent of disease on chest radio-
graphs and smear grade, were recorded. The extent of
disease on chest radiographs was classified as normal,
mild, moderate, or far advanced using a validated, stan-
dardized scheme [31], with lesions recorded by an inde-
pendent reader who was blinded to smear and culture
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performed at either the National TB Reference Laboratory
(NTRL) or the Joint Clinical Research Centre (JCRC) TB
Laboratory. Isolates were confirmed as MTB using the
BACTEC® para-nitro-acetyl amino-hydroxy-propiophenone
(NAP) susceptibility method [32] and later stored at – 80°C
in 7H9 broth supplemented with OADC and glycerol for
future analyses.
The institutional review boards and ethics committees
at Case Western Reserve University, Makerere University,
and the Ugandan AIDS Research Council, and the Uganda
National Council for Science and Technology approved
the study protocols. All patients gave written informed
consent for study participation, including pre- and post-
HIV test counseling.Extraction of MTBC genomic DNA from stored isolates
A total of 1,746 isolates were stored in replicates at either
JCRC or NTRL laboratories at – 80°C. Isolates corre-
sponding to an individual patient were selected for geno-
typing. To extract DNA, the selected isolates were thawed
overnight at – 20°C and later at room temperature for
12 h. The vials were centrifuged at 15,000 g for 30 min
and the pellet washed twice with 500 μl of Qiagen PCR
water. The final pellet was re-suspended in 100 μl of
Qiagen PCR-water, heated at 95°C for 30 minutes to kill
and lyse the bacilli and later sonicated for 15 min at room
temperature. The extracted genomic DNA in the super-
natant was recovered by centrifugation at 15,000 g for
30 min; the latter was used immediately in the real time
PCR (RT-PCR) assay or stored at −20°C for future use.Genotyping MTBC isolates with Single Nucleotide
Polymorphic (SNP) markers by RT-PCR assay
To ascertain the lineage of an MTB isolate, RT-PCR
(Roche Light Cycler® 480) was performed using specific
primers and hybridization probes (HyProbe, FRET probes)
containing SNPs designed based on the work pub-
lished by Comas et al. [9] and Hershberg et al. [10]
(See Additional file 1: Table S1). RT-PCR analysis involved,
amplification (40 cycles of 95°C for 10s, 57/53/51°C for
10s and 72°C for 10s) of the target region(s) to generate
amplicons for melting curve analysis. Melting curves were
analyzed using lightCycler® software version 1.5 to assign
an isolate to a particular lineage depending on the melting
temperature (Tm) at which the hybridization probes
dissociates from the amplicons. For validation pur-
poses, Long Sequence Polymorphism PCR (LSP-PCR)
analysis was performed as previously described [1,20].
In all the assays, we used MTB L4-U genomic DNA
from our laboratory, H37Rv genomic DNA (Lineage 4)
and Lineage 3 (Central Asian strain) genomic DNA
(Courtesy of Mark Nicol) as positive control DNA.Identification of MTBC lineages in the clinical isolates
collected from peri-urban Kampala
A total of eight (8) SNPs, 3 for identifying MTB Uganda
(L4-U): (Rv0006_0238n, Rv0040c-0619n and Rv2949c-
0375s); 2 for MTB Lineage 4: (Rv 0407-0960s and Rv
2962c-0711) and then 3 for MTB Lineage 3: (Rv
0129c_0472n, Rv 2959c-0219n and Rv 3133c-0419) each
with its accompanying designed primers and probes
were optimized for use in RT-PCR SNP assays to iden-
tify MTBC lineages on the basis of differences in melting
temperature (Tm). Since the SNPs identifying each
lineage were mutually exclusive, we selected a single
SNP from each lineage, which provided reliable results,
for genotyping the 1,746 MTB isolates. For the Uganda
family sub lineage we selected 2 SNPs, one for identify-
ing Uganda I and the other for Uganda II MTB (See
Additional file 1: Table S1). Genotyping results based on
the designed RT-PCR SNP assay were consistent with
that based on long sequence polymorphism (LSP) (data
not shown).
Statistical analysis
Patient characteristics were compared using the chi-square
test for binary data and Student’s t-test for continuous vari-
ables. A series of univariate and multivariable logistic re-
gression models were fitted to evaluate the relationship
between MTB lineage (primary independent variable) and
severity of TB disease on chest radiograph (cavitary TB) or
smear status (dependent variable). Lung cavitation as a
radiographic variable was used as a measure for severity of
disease since it is associated with worse symptoms of TB
[33,34,35]. Age, sex, HIV status and other patient charac-
teristics were used as covariates (See Table 1).
In order to predict the transmission dynamics over a
span of 18 years, we performed a trend analysis using
Poisson regression analysis with MTB lineage as the
main predictor variable and adjustment for years. All
analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC).
Results
Overall and time-point prevalence of MTBC lineages in
peri-urban Kampala from 1992–2009
In a RT-PCR SNP genotyping assay, a total of 1,746
MTBC isolates, each from a different TB patient, were
analyzed. Overall, 63% (1092/1,746) were L4-U, 22%
(394/1,746) were other Lineage 4 strains [from now on-
wards these shall be referred to as Lineage 4 non
Uganda (L4-NU)], and 11% (187/1,746) Linage 3 (L3).
The remaining 73 (4%) strains could not be classified
based on the genotyping techniques used (Additional file 2:
Figure S1). Next, we determined the point prevalence of
the three predominant MTBC lineages during the
previous 18 years (1992 to 2009). The data suggest that
Table 1 Distribution of patient variables across the 3 main MTB lineages in peri-urban Kampala
Variable Category Patients characteristics (n, %) L4-U (n=788) L4-NU (n=289) L 3 (n=136) P-value*
Age1 > 30 years 757 (69) 503 (70) 173 (66) 81 (68) 0.44
≤ 30 years 340 (31) 213 (30) 89 (34) 38 (32)
Sex2 Female 503 (46) 325 (45) 120 (46) 58 (49) 0.79
Male 594 (54) 391 (55) 142 (54) 61 (51)
HIV status3 Negative 669 (65) 450 (66) 157 (62) 62 (60) 0.29
positive 367 (35) 230 (34) 95 (38) 42 (40)
Cavity4 No 441 (47) 296 (48) 106 (48) 39 (39) 0.25
Yes 500 (53) 324 (52) 115 (52) 61 (61)
Ethnicity5 Non-bantu 64 (6) 39 (6) 14 (6) 11 (9) 0.27
Bantu 984 (94) 641 (94) 238 (94) 105 (91)
Smoking6 status Never smoked 659 (62) 443 (65) 155 (60) 61 (52) 0.03
Current or ever smoked 401 (38) 243 (35) 102 (40) 56 (48)
BMI7 Weight loss 557 (49) 374(50) 121(44) 62(48) 0.19
No loss 588 (51) 368(50) 154(56) 66(52)
Level of education8 Low 377 (35) 248 (36) 93(36) 36(31) 0.52
High 688 (65) 444(64) 163(64) 81(69)
Drinking alcohol9 Yes 162 (21) 106 (21) 40(21) 16(22) 0.99
No 611 (79) 402(79) 151(79) 58(78)
Income10 Low 270 (46) 162(44) 69(46) 39 (61) 0.048
High 314 (54) 203(56) 82 (54) 29 (39)
diabetic Patients11 Yes 12 (1) 8(2) 3(2) 1(2) 0.97
No 922 (99) 604(98) 224(98) 94(98)
Presence of BCG scar12 Yes 756 (62) 488 (62) 183 (63) 85 (63) 0.92
No 456 (38) 299 (38) 106 (37) 51 (38)
Night sweets13 No 533 (47) 340(46) 133(49) 60 (47) 0.69
Yes 608 (53) 401 (54) 139(51) 68 (53)
TB in the past14 Yes 17 (2) 10 (2) 3 (2) 4 (4) 0.18
No 953 (98) 619 (98) 239 (98) 95 (96)
Hemoptysis15 No 173 (15) 111(15) 43(16) 19 (15) 0.95
Yes 972 (85) 632(85) 231(84) 109 (85)
Swollen lymph nodes16 No 46 (6) 26 (5) 16 (8) 4 (5) 0.26
Yes 727 (94) 482(95) 175(91) 70 (95)
Extent of lung involvement17 Normal/mild 733 (73) 475 (72) 180 (75) 78 (76) 0.58
Advance/far advanced 271 (27) 185 (28) 61 (25) 25 (24)
Smear grade18 ≤10 AFB/field 227 (33) 146 (33) 65 (37) 16 (24) 0.1377
>10 AFB/field 454 (67) 294 (67) 109 (63) 51 (76)
*p-value obtained by chi-square statistic; 1 = 116 missed data for age, 2 = 116 missed data for sex, 3 = 177 missed data for HIV status, 4 = 272 missed data for
cavity, 5 = 165 missed data for ethnicity, 6 = 153 missed data for smoking status, 7= 68 missed data for BMI, 8= 148 missed data for level of education, 9= 440
missed data for drinking alcohol, 10= 633 missed data for income, 11= 279 missed data for diabetes history, 12= 1 missed data for BCG status, 13 = 72 missed
data for night sweating, 14= 243 missed data for history of TB, 15= 68 missed data for hemoptysis, 16 = 440 missed data for swollen glands, 17= 209 missed data
for extent of lung involvement, 18=532 misses data of smear grade.
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(Additional file 3: Figure S2). However, there were
significant differences in MTBC lineage frequency
over time (Poisson regression analysis, P<0.0001), withL4-U having the highest frequency during the whole
study period, followed by L4-NU and L3. The differ-
ence in frequencies remained significantly different
over the years examined (Figure 1). To explore the
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Figure 1 M. tuberculosis Uganda (L4-U) dominance over L4-NU and L3 has been stable between 1992–2009. MTBC lineages were
identified as described in the legend of Figure 1. Each data point [1992 (n=109), 1993 (n=71) 1994 (n=94), 1995 (n=73) 1996 (n=80), 1997 (n=82),
1998 (n=42), 1999 (n=63) 2000 (n=88), 2001 (n=68) 2002 (n=151), 2003 (n=148), 2004 (n=87), 2005 (n=119) 2006 (n=70), 2007 (n=132) 2008
(n=102), 2009 (n=94)] represent proportions of MTBC lineages observed per year.
Table 2 Association between MTB lineages and patient
characteristics with cavitary TB
Variable Category Odds
Ratio©
95% CI *P-value
Lineage Lineage L4-NU 1 - -
Uganda (L4-U) 0.90 0.69-1.18 0.45
Lineage 3 1.43 0.94-2.19 0.10
Age > 30 years 1
≤ 30 years 1.13 0.85-1.49 0.40
Sex Female 1
Male 1.24 0.96-1.60 0.10
HIV status Negative 1
Positive 0.78 0.596-1.03 0.08
Smoking status Never smoked 1
Current or ever smoked 4.78 3.41-6.69 <0.0001
Income High 1
Low 2.13 1.52-2.97 <0.0001
Hemoptysis Yes 1
No 2.10 1.46-3.03 <0.001
*p-value obtained by logistic regression analysis; ©Unadjusted OR = Odds ratio.
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L4-U compared to the other lineages circulating in
Kampala, we compiled and analyzed detailed clinical data.
Patient characteristics across MTBC lineages
Of the 1,746 MTBC isolates we genotyped initially, we
excluded 533 (31%) for this part of the analysis because
they lacked patient information or were of unknown
lineage. Hence, a total of 1,213 (69%) isolates remained
corresponding to one TB patient each. The detailed pa-
tient characteristics of all of these patients are listed in
Table 1.
Our univariate analysis taking lineage as the outcome
showed that the proportions of patients infected with
each MTBC lineage did not differ according to age, sex,
HIV/TB co-infection, ethnicity, BMI, level of education,
taking alcohol, history of diabetes, presence of BCG scar,
night sweats, history of TB in the past, hemoptysis,
swollen glands, extent of lung involvement or smear
grade status (Table 1). However, we found that the pro-
portion of TB patients with cavitary disease differed by
MTBC lineage; however, this difference was not statisti-
cally significant (Table 1). Since cavitary disease is posi-
tively correlated with transmission and thus a measure
of “virulence” [36], we decided to further investigate this
difference, while controlling for the additional variables
associated with cavitary TB.
Patient risk factors associated with cavitary TB in
peri-urban Kampala
Our univariate analysis taking cavitary TB as the out-
come confirmed that the difference between MTBC line-
ages was not statistically significant. But other factorswere significantly associated with cavitary TB and in-
cluded a history of smoking (OR 4.78; 95% CI 3.41-6.69),
low income (OR 2.13, 95% CI 1.52-2.97 and hemoptysis
(OR 2.10 95% CI 1.46-3.03 (Table 2). Our multivariable
logistic regression analysis with MTBC lineage as the
main predictor and after adjusting for age, HIV status,
history of smoking, income of the patients, and
hemoptysis, again confirmed that the odds of having
cavitary TB did not differ significantly between the 3
MTBC lineages (Table 3). The factors independently
Table 3 Multivariate analysis determining independent
risk factors for development of cavitary TB
Variable Category Odds
ratio®
95% CI P-value*
Lineage Lineage L4-NU 1 - -
Uganda (L4-U) 1.08 0.78-1.51 0.6422
Lineage 3 1.32 0.78-2.22 0.296
Age > 30 years 1 - -
≤ 30 years 0.866 0.63-1.20 0.38
HIV status Negative 1 - -
Positive 0.62 0.45-0.84 0.0023
Smoking status Never smoked 1 - -
Current or ever smoked 4.76 3.33-6.84 <0.0001
Income High 1
Low 2.10 1.47-3.01 <0.0001
Hemoptysis No 1 - -
Yes 1.64 1.10-2.42 0.014
*p-value obtained by logistic regression analysis; ®adjusted OR = Odds ratio.
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odds ratio (aOR) 4.76, 95% CI 3.33-6.84), low income
(aOR 2.10, 95%CI 1.47-3.01), signs of hemoptysis (aOR
1.64, 95%CI 1.10-2.42) and HIV status (aOR 0.62 95% CI
0.45-0.84 for HIV-positive patients) (Table 3).Discussion
In this study, we sought to understand the basis for the
long-term success of the MTB Uganda family in
Kampala, Uganda. First, we examined the MTBC popu-
lation structure and changes in prevalence of the differ-
ent MTBC lineages circulating in Kampala during the
last 18 years. Secondly, we investigated the risk factors
associated with cavitary TB. Our data show that in peri-
urban Kampala there are 3 dominant MTBC lineages
causing TB, with L4-U being the most predominant and
stable for the last 18 years, followed by the L4-NU and
L3. Additionally, our multivariate results also showed
that this long-term success of L4-U was not due to in-
creased virulence when considering cavitary TB as a
proxy, even though cavitary TB per se was independ-
ently associated with other known risk factors such as
smoking, low socio-economic status and HIV-negative
status [37-42]. We also note that, from out recruitment
criteria only smear positive patients were enrolled as
index probably this could have reduced our chances of
finding any association of MTB lineage with cavitary TB.
Nevertheless, among the contacts 80 % of the patients
were smear negative and still this category of patients
showed no association of MTB Uganda family with cavi-
tation in a univariate analysis (data not shown).Prevalence of MTB lineages over time in peri-urban
Kampala
Our data reiterate earlier findings that reported domin-
ance of L4-U in Uganda [7,8,20]. In addition, the large
sample size and longitudinal nature of our sample
allowed us to investigate trends over time. We found
that the dominance of L4-U over other Lineage 4 strains
and Lineage 3 has been constant for at least the last 18
years, even with episodes of HIV and different interven-
tions such as introduction of anti-retrovirus drugs and
promotion of condom use. Taken together, these results
are in agreement with the global phylogeography of
MTBC, and show that the association between particular
MTBC lineages and specific geographic settings is long-
standing [2,3,6].
Phenotypes of MTB lineages in peri-urban Kampala
There is increasing evidence from experiments in animal
models and from clinical studies indicating that MTBC
strains differ in their phenotypes [3,5,18]. For instance,
the virulent H37Rv laboratory strain of MTBC induces
less apoptosis in macrophages that the avirulent H37Ra
strain [43]. Investigations in animal models have also in-
dicated that virulence also varies between MTBC clinical
strains [24,44-47]. Data from clinical cohorts have dem-
onstrated that some strains are associated with fever
[48], more severe disease [20], higher transmissibility
[49], increased ability to progress from latency to active
disease [50], extra pulmonary disease [51-53], and HIV
co-infection [1,28]. Given that background, in this study,
we tested the hypothesis that increased virulence could
be responsible for the long-term success of L4-U in
Kampala. We defined virulence as the ability of MTB
lineage to cause cavitary TB, hence causing severe dis-
ease which is more transmissible [36,54]. Our data
showed that all lineages identified in this study area had
comparable odds of causing cavitary TB. This lack of as-
sociation remained even after adjusting for socio-
economic and patient clinical characteristics. However,
this is contrary to an earlier smaller study that observed
that L4-U was more virulent [20]. The fact that we iden-
tified other clinical risk factors previously shown to be
associated with cavitary disease [37,55-61] serves as a
“positive control” in our study, and supports our nega-
tive finding of the lack of association of MTBC lineage
with cavitary disease.
Association between MTBC variants and their human
hosts
If the long-term dominance of L4-U is not due to in-
creased virulence, what else could be at the basis of its
success compared to other lineages in Kampala? MTBC
is known to exhibit a strong phylogeographical popula-
tion structure [1,28], which is also reflected at the
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family of MTBC is a sub-lineage of Lineage 4 and almost
exclusively found in West-Africa [62]. Similarly, L4-U is
mainly found in Uganda and neighboring countries, and
rarely found elsewhere. Another important feature of the
phylogeography of MTBC is that it remains stable even in
large cosmopolitan settings such as San Francisco, London
and Montreal, where at least some degree of intermingling
between local and immigrant host and MTBC populations
could be expected [1,6,26,63]. Moreover, several studies
have shown that MTBC preferably transmits in sympatric
host populations [1,28]. Based on these observations, it has
been hypothesized that different MTBC lineages might
have adapted to different human population, possibly as a
consequence of the long co-evolutionary history of MTBC
and its human host [1,2,5,6,10,28]. Our observation that
L4-U has been dominating in Kampala for at least 2
decades is consistent with this hypothesis. However, much
more work is needed to substantiate this notion, including
studies that investigate the interaction between human and
MTBC genetic diversity [27,64-67].
Limitations of the study
First, this study defined disease outcome at presentation;
this could have limited our ability to detect other parame-
ters that contribute to disease outcome as the disease pro-
gresses. Second, our study was neither population-based
nor completely random, possibly bringing about some se-
lection bias. Nevertheless, the strength of our study is that
it is based on patient information and laboratory data col-
lected from two large, well-characterized and systematic-
ally followed up studies conducted over a long period of
time.
Conclusions
In summary, we observed 3 main MTBC lineages circu-
late in peri-urban Kampala, with the L4-U being pre-
dominant for the last 2 decades. We found that none of
these MTBC lineages were associated with increased risk
for cavitary TB.
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